|
🛑 N-nitroso Ticagrelor
|
|
32
|
4322
|
August 8, 2026
|
|
N Nitroso Tadalfil
|
|
19
|
1430
|
August 7, 2026
|
|
Nitrosamine Control Strategy for Products within the Scope of ICH S9
|
|
5
|
327
|
August 7, 2026
|
|
Differential Mutagenic Response of Rat Liver and Lung to Nicotine-Derived Nitrosamine Ketone (NNK)-Pub
|
|
0
|
103
|
August 5, 2026
|
|
Determination of Trace Nitrosamines in Plastic Pharmaceutical Packaging Materials
|
|
2
|
191
|
August 4, 2026
|
|
Nitrosamine risk assessment for short-term therapies: lifetime assumptions versus less-than-lifetime (LTL) exposure
|
|
2
|
199
|
August 4, 2026
|
|
🦺 A new Home, the same community!
|
|
38
|
714
|
August 3, 2026
|
|
🇺🇸 FDA updates 'estimated duration' dates on Recommended Interim AI limits
|
|
1
|
244
|
August 3, 2026
|
|
🇺🇸 FDA Control of Nitrosamine Impurities in Human Drugs revision2
|
|
63
|
6932
|
October 3, 2025
|
|
N-Nitroso meglumine
|
|
34
|
2986
|
August 1, 2026
|
|
N-Nitroso Abacavir Impurity possibility in physical state as standard
|
|
5
|
153
|
August 1, 2026
|
|
QSAR Toolbox - Free software. Any experience?
|
|
22
|
2631
|
July 31, 2026
|
|
Integrating nitrosamine theoretical formation into Translational Pharmaceutics: Mitigating risks during accelerated formulation development in early phase clinical studies-Pub
|
|
0
|
126
|
July 28, 2026
|
|
Nitrosamine Workshop, Hyderabad, August 19 & 20
|
|
3
|
384
|
July 27, 2026
|
|
N-Nitroso Desmethyl Tramadol - Standard
|
|
3
|
243
|
July 27, 2026
|
|
Nitrosamines: Mass Spectrometry-Based Analytical Procedures Criterias
|
|
12
|
4698
|
July 25, 2026
|
|
Complex versus simple N-nitrosamines: Comprehensive genotoxicity and in silico carcinogenicity assessment toward future testing paradigms -Pub
|
|
8
|
755
|
July 25, 2026
|
|
Which Molecule Is Involved in the Nitrosation Reaction of Pharmaceuticals: NO or NO 2 ? -Pub
|
|
3
|
275
|
July 24, 2026
|
|
CrN-coated punches and nitrosamine risk
|
|
0
|
88
|
July 23, 2026
|
|
AI limit for N-nitroso betahistine?
|
|
32
|
4803
|
July 23, 2026
|
|
Establishment of Limits in ppm (mg/kg) for Drug Products
|
|
2
|
261
|
July 22, 2026
|
|
MEGLUMINE (Methylglucamine)
|
|
31
|
4397
|
July 20, 2026
|
|
N-nitrosoproline
|
|
0
|
113
|
July 20, 2026
|
|
Determining Low PPB Levels of Nitrite in Polymeric Excipients
|
|
2
|
415
|
July 19, 2026
|
|
Less than daily administration
|
|
7
|
456
|
July 19, 2026
|
|
Nitrite Levels in Reverse Osmosis Water
|
|
7
|
401
|
July 17, 2026
|
|
Process-dependent N-nitroso-ketamine formation during ketamine active pharmaceutical ingredient manufacturing: part I impact of process design, solvent selection, and activated carbon-Pub
|
|
1
|
160
|
July 15, 2026
|
|
Trace-level LC–MS/MS quantification of two nitrosamine impurities formed from terazosin-related impurities in pharmaceutical products and greenness assessment-Pub
|
|
2
|
211
|
July 15, 2026
|
|
Requirements for NAs assessment in Russia
|
|
8
|
456
|
July 10, 2026
|
|
In Vitro Metabolism Study of NDSRIs
|
|
4
|
427
|
July 9, 2026
|